Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28


A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.

Kollmorgen G, Palme K, Seidl A, Scheiblich S, Birzele F, Wilson S, Clemens C, Voss E, Kaufmann M, Hirzel K, Rieder N, Krippendorff BF, Herting F, Niederfellner G.

Sci Rep. 2017 Dec 22;7(1):18086. doi: 10.1038/s41598-017-17329-7.


Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.

Leshem Y, O'Brien J, Liu X, Bera TK, Terabe M, Berzofsky JA, Bossenmaier B, Niederfellner G, Tai CH, Reiter Y, Pastan I.

Cancer Immunol Res. 2017 Aug;5(8):685-694. doi: 10.1158/2326-6066.CIR-16-0330. Epub 2017 Jul 3.


Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis.

Liu XF, Xiang L, Zhou Q, Carralot JP, Prunotto M, Niederfellner G, Pastan I.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10666-71. doi: 10.1073/pnas.1611481113. Epub 2016 Sep 6.


TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.

Castoldi R, Schanzer J, Panke C, Jucknischke U, Neubert NJ, Croasdale R, Scheuer W, Auer J, Klein C, Niederfellner G, Kobold S, Sustmann C.

Protein Eng Des Sel. 2016 Oct;29(10):467-475. doi: 10.1093/protein/gzw037. Epub 2016 Aug 29.


Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.


Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor.

Stahl S, da Silva Mateus Seidl AR, Ducret A, Kux van Geijtenbeek S, Michel S, Racek T, Birzele F, Haas AK, Rueger R, Gerg M, Niederfellner G, Pastan I, Brinkmann U.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10732-7. doi: 10.1073/pnas.1512863112. Epub 2015 Aug 10.


Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results.

Mason-Osann E, Hollevoet K, Niederfellner G, Pastan I.

Sci Rep. 2015 Jun 26;5:10832. doi: 10.1038/srep10832.


Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells.

Sivasubramaniyan K, Harichandan A, Schilbach K, Mack AF, Bedke J, Stenzl A, Kanz L, Niederfellner G, Bühring HJ.

Glycobiology. 2015 Aug;25(8):902-17. doi: 10.1093/glycob/cwv032. Epub 2015 May 15.


Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.

Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S.

J Natl Cancer Inst. 2014 Nov 24;107(1):364. doi: 10.1093/jnci/dju364. Print 2015 Jan.


Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.

Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I.

Mol Cancer Ther. 2014 Nov;13(11):2653-61. doi: 10.1158/1535-7163.MCT-14-0132. Epub 2014 Sep 19.


In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.

Hollevoet K, Mason-Osann E, Liu XF, Imhof-Jung S, Niederfellner G, Pastan I.

Mol Cancer Ther. 2014 Aug;13(8):2040-9. doi: 10.1158/1535-7163.MCT-14-0089-T. Epub 2014 Jun 13. Erratum in: Mol Cancer Ther. 2015 Jul;14(7):1763.


Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death.

Paradisi A, Creveaux M, Gibert B, Devailly G, Redoulez E, Neves D, Cleyssac E, Treilleux I, Klein C, Niederfellner G, Cassier PA, Bernet A, Mehlen P.

EMBO Mol Med. 2013 Dec;5(12):1821-34. doi: 10.1002/emmm.201302654. Epub 2013 Oct 8.


Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy.

Kollmorgen G, Niederfellner G, Lifke A, Spohn GJ, Rieder N, Harring SV, Bauss F, Burtscher H, Lammers R, Bossenmaier B.

Mol Oncol. 2013 Dec;7(6):1142-51. doi: 10.1016/j.molonc.2013.08.009. Epub 2013 Sep 3.


Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C.

Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19.


A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.

Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C.

Oncogene. 2013 Dec 12;32(50):5593-601. doi: 10.1038/onc.2013.245. Epub 2013 Jul 1.


RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.

Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, Hopfner KP, Niederfellner G, Bossenmaier B.

Cancer Res. 2013 Aug 15;73(16):5183-94. doi: 10.1158/0008-5472.CAN-13-0099. Epub 2013 Jun 18.


Response to: monoclonal antibodies targeting CD20.

Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Umaña P, Niederfellner G.

MAbs. 2013 May-Jun;5(3):337-8. doi: 10.4161/mabs.24108. Epub 2013 Mar 14. No abstract available.


Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.

Kollmorgen G, Bossenmaier B, Niederfellner G, Häring HU, Lammers R.

PLoS One. 2012;7(12):e53050. doi: 10.1371/journal.pone.0053050. Epub 2012 Dec 31.


Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.

Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Umaña P, Niederfellner G.

MAbs. 2013 Jan-Feb;5(1):22-33. doi: 10.4161/mabs.22771. Epub 2012 Dec 4.


Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties.

Castoldi R, Jucknischke U, Pradel LP, Arnold E, Klein C, Scheiblich S, Niederfellner G, Sustmann C.

Protein Eng Des Sel. 2012 Oct;25(10):551-9. Epub 2012 Aug 29.


Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.

Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, Franke A, Wiechmann K, Jenewein S, Slootstra JW, Timmerman P, Brännström A, Lindstrom F, Mössner E, Umana P, Hopfner KP, Klein C.

Blood. 2011 Jul 14;118(2):358-67. doi: 10.1182/blood-2010-09-305847. Epub 2011 Mar 28.


Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines.

Franke A, Niederfellner GJ, Klein C, Burtscher H.

PLoS One. 2011 Feb 18;6(2):e16596. doi: 10.1371/journal.pone.0016596.


Liver TAG transiently decreases while PL n-3 and n-6 fatty acids are persistently elevated in insulin resistant mice.

Scheja L, Toedter K, Mohr R, Niederfellner G, Michael MD, Meissner A, Schoettler A, Pospisil H, Beisiegel U, Heeren J.

Lipids. 2008 Nov;43(11):1039-51. doi: 10.1007/s11745-008-3220-3. Epub 2008 Sep 2.


Partitioning-defective protein 6 regulates insulin-dependent glycogen synthesis via atypical protein kinase C.

Weyrich P, Kapp K, Niederfellner G, Melzer M, Lehmann R, Häring HU, Lammers R.

Mol Endocrinol. 2004 May;18(5):1287-300. Epub 2004 Feb 19.


Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.

Hennige AM, Lammers R, Arlt D, Höppner W, Strack V, Niederfellner G, Seif FJ, Häring HU, Kellerer M.

Mol Cell Endocrinol. 2000 Sep 25;167(1-2):69-76.


Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.

Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A.

EMBO J. 1995 Sep 1;14(17):4267-75.


Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor.

Strawn LM, Mann E, Elliger SS, Chu LM, Germain LL, Niederfellner G, Ullrich A, Shawver LK.

J Biol Chem. 1994 Aug 19;269(33):21215-22.

Supplemental Content

Loading ...
Support Center